EUCTR2008-000500-83-LV进行中（未招募）不适用
A phase II exploratory, ascending dose, multicentre study to investigate the pharmacodynamics, pharmacokinetics, safety and tolerability, of BIM23A760 in acromegalic patients.
Beaufour Ipsen Pharma0 个研究点目标入组 24 人开始时间: 2008年10月31日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •All patients must fulfil the following:
- •1. The patient has provided written informed consent prior to any study related procedures.
- •2. The patient age is between 18 and 75 years inclusive.
- •3. The patient is male, or a woman aged over 60 who has been post menopausal for at least 5 years. In addition women with a documented infertility (natural or acquired) may be included.
- •4. The patient must agree that, if their partner is at risk of becoming pregnant, they will use an effective method of contraception as defined in the ICH M3 guideline, and this should be continued for two months after the Investigational Medicinal Product (IMP) administration.
- •5. The patient must have documentation supporting the diagnosis of acromegaly, including elevated GH and/or insulin-like growth factor - I (IGF-I) levels.
- •6. The patient has a mean serum GH concentration > 4µg/l during a 5h profile and an IGF-I serum level above normal during the screening period.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients will not be included in the study if:
- •1. The patient has undergone pituitary surgery within 3 months prior to study entry.
- •2. The patient has undergone radiotherapy anytime prior to study entry.
- •3. It is anticipated that the patient will receive pituitary surgery or radiotherapy during the study.
- •4. The patient has received long acting somatostatin analogues within 6 months prior to study entry.
- •5. The patient has received dopamine agonist or short acting octreotide within 1 month before entering the study.
- •6. The patient has received GH antagonist at anytime prior to study entry.
- •7. The patient is known for not being controlled by somatostatin analogues at anytime prior to study entry.
- •8. The patient has any known uncontrolled cardiovascular disease and/or concomitant medication(s) associated with risk of severe hypotension.
- •9. The patient has any known valvular disease.
- •10. The patient has any known uncontrolled metabolic disease.
- •11. The patient has insulin-treated diabetes or HbA1c > 7.5%.
- •12. The patient has clinically significant hepatic abnormalities and/or AST/ALT > 3 ULN during the screening period.
- •13. The patient has any severe renal or hepatic insufficiency.
- •14. The patient is receiving any Hormone Replacement Therapy (HRT).
- •15. The patient is receiving neuroleptic antipsychotic/antiemetic drugs.
- •16. The patient has abnormal findings during the screening period, any other medical condition(s) or laboratory findings that, in the opinion of the Investigator, might jeopardise the patient’s safety.
- •17. The patient has been treated with any other IMP prior to the first study visit without undergoing a wash-out period of 7 times the elimination half-life of the investigational compound.
- •18. The patient has a known hypersensitivity to any of the test materials or related compounds.
- •19. The patient is likely to require treatment during the study with drugs that are not permitted by the study protocol.
- •20. The patient has a history of, or known current, problems with alcohol or drug abuse.
- •21. The patient has any mental condition rendering the patient unable to understand the nature, scope and possible consequences of the study, and/or evidence of an uncooperative attitude
研究者
相似试验
进行中（未招募）
不适用
A phase II exploratory, ascending dose, multicentre study to investigate the pharmacodynamics, pharmacokinetics, safety and tolerability, of BIM23A760 in acromegalic patients.MedDRA version: 9.1Level: LLTClassification code 10000599Term: AcromegalyAcromegalyEUCTR2008-000500-83-BEIpsen Pharma SAS24
进行中（未招募）
不适用
A phase II exploratory, ascending dose, multicentre study to investigate the pharmacodynamics, pharmacokinetics, safety and tolerability, of BIM23A760 in acromegalic patients.AcromegalyMedDRA version: 9.1Level: LLTClassification code 10000599Term: AcromegalyEUCTR2008-000500-83-LTIpsen Pharma24
进行中（未招募）
不适用
A PHASE II EXPLORATORY, ASCENDING DOSE, MULTICENTRE STUDY TOINVESTIGATE THE PHARMACODYNAMICS, PHARMACOKINETICS, SAFETY ANDTOLERABILITY, OF BIM 23A760 IN ACROMEGALIC PATIENTS. - NDAcromegaly.MedDRA version: 9.1Level: LLTClassification code 10000599Term: AcromegalyEUCTR2008-000500-83-ITBEAUFOUR IPSEN PHARMA24
招募中
1 期
Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the BloodMedDRA version: 21.0Level: LLTClassification code: 10060558Term: Acute myeloid leukemia recurrent Class: 10029104MedDRA version: 21.0Level: LLTClassification code: 10000886Term: Acute myeloid leukemia Class: 10029104MedDRA version: 21.0Level: PTClassification code: 10076230Term: Fms-like tyrosine kinase 3 positive Class: 100000004848Acute Myeloid LeukemiaCTIS2023-510009-16-00Daiichi Sankyo Inc.65
未知
2 期
A Phase 2, Multicenter, Open-label, Dose-escalation Study to Evaluate the Safetyand Tolerability of Intravenous Dose of MEDI-546, a Human Monoclonal Antibody Directed Against Type I Interferon Receptor (IFNAR), in Japanese Subjects With Active Systemic Lupus Erythematosus (SLE)Systemic Lupus ErythematosusJPRN-jRCT2080221785AstraZeneca